trastuzumab emtansine

Ukraine

Drugs containing this active substance

KADSILA

The drug is indicated for the treatment of adult patients with HER2-positive early breast cancer (following prior taxane and HER2-targeted therapy) or for the treatment of HER2-positive unresectable locally advanced or metastatic breast cancer.

Form: powder for concentrate for infusion solution

Active substance	Dosage
trastuzumab emtansine	100 mg

ATC: L01FD03

Manufacturer: F. Hoffmann-La Roche Ltd (manufacturing of unpackaged products, primary packaging, secondary packaging, quality control testing, batch release)

KADSILA®

The drug is used for the treatment of adults with HER2-positive early breast cancer (following prior taxane and HER2-targeted therapy) or for the treatment of HER2-positive unresectable locally advanced or metastatic breast cancer.

Form: powder for concentrate for infusion solution

Active substance	Dosage
trastuzumab emtansine	160 mg

ATC: L01FD03

Manufacturer: F. Hoffmann-La Roche Ltd (manufacturing of unpackaged products, primary packaging, secondary packaging, quality control testing, batch release)